About Perilipin-4
Perilipin-4 (PLIN4) is a protein
from Homo sapiens identified by UniProt accession
Q96Q06, 1371 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Perilipin-4 |
|---|
| UniProt accession | Q96Q06 |
|---|
| Gene | PLIN4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1371 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (85)
Diseases linked to this target (Open Targets).
- waist-hip ratio · score 0.50
- body weights and measures · score 0.42
- mean corpuscular hemoglobin concentration · score 0.39
- mean corpuscular volume · score 0.36
- erythrocyte count · score 0.32
- BMI-adjusted waist-hip ratio · score 0.30
- Immature Reticulocyte Fraction Measurement · score 0.29
- body fat percentage · score 0.25
- hip circumference · score 0.24
- mean corpuscular hemoglobin · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96Q06-F1 | alphafold | PREDICTED | 34.70 | — |
Amino-acid sequence (1371 residues)
MSAPDEGRRD PPKPKGKTLG SFFGSLPGFS SARNLVANAH SSARARPAAD PTGAPAAEAA QPQAQVAAHP EQTAPWTEKE LQPSEKMVSG AKDLVCSKMS RAKDAVSSGV ASVVDVAKGV VQGGLDTTRS ALTGTKEVVS SGVTGAMDMA KGAVQGGLDT SKAVLTGTKD TVSTGLTGAV NVAKGTVQAG VDTTKTVLTG TKDTVTTGVM GAVNLAKGTV QTGVETSKAV LTGTKDAVST GLTGAVNVAR GSIQTGVDTS KTVLTGTKDT VCSGVTGAMN VAKGTIQTGV DTSKTVLTGT KDTVCSGVTG AMNVAKGTIQ TGVDTSKTVL TGTKDTVCSG VTGAMNVAKG TIQTGVDTTK TVLTGTKNTV CSGVTGAVNL AKEAIQGGLD TTKSMVMGTK DTMSTGLTGA ANVAKGAMQT GLNTTQNIAT GTKDTVCSGV TGAMNLARGT IQTGVDTTKI VLTGTKDTVC SGVTGAANVA KGAVQGGLDT TKSVLTGTKD AVSTGLTGAV NVAKGTVQTG VDTTKTVLTG TKDTVCSGVT SAVNVAKGAV QGGLDTTKSV VIGTKDTMST GLTGAANVAK GAVQTGVDTA KTVLTGTKDT VTTGLVGAVN VAKGTVQTGM DTTKTVLTGT KDTIYSGVTS AVNVAKGAVQ TGLKTTQNIA TGTKNTFGSG VTSAVNVAKG AAQTGVDTAK TVLTGTKDTV TTGLMGAVNV AKGTVQTSVD TTKTVLTGTK DTVCSGVTGA ANVAKGAIQG GLDTTKSVLT GTKDAVSTGL TGAVKLAKGT VQTGMDTTKT VLTGTKDAVC SGVTGAANVA KGAVQMGVDT AKTVLTGTKD TVCSGVTGAA NVAKGAVQTG LKTTQNIATG TKNTLGSGVT GAAKVAKGAV QGGLDTTKSV LTGTKDAVST GLTGAVNLAK GTVQTGVDTS KTVLTGTKDT VCSGVTGAVN VAKGTVQTGV DTAKTVLSGA KDAVTTGVTG AVNVAKGTVQ TGVDASKAVL MGTKDTVFSG VTGAMSMAKG AVQGGLDTTK TVLTGTKDAV SAGLMGSGNV ATGATHTGLS TFQNWLPSTP ATSWGGLTSS RTTDNGGEQT ALSPQEAPFS GISTPPDVLS VGPEPAWEAA ATTKGLATDV ATFTQGAAPG REDTGLLATT HGPEEAPRLA MLQNELEGLG DIFHPMNAEE QAQLAASQPG PKVLSAEQGS YFVRLGDLGP SFRQRAFEHA VSHLQHGQFQ ARDTLAQLQD CFRLIEKAQQ APEGQPRLDQ GSGASAEDAA VQEERDAGVL SRVCGLLRQL HTAYSGLVSS LQGLPAELQQ PVGRARHSLC ELYGIVASAG SVEELPAERL VQSREGVHQA WQGLEQLLEG LQHNPPLSWL VGPFALPAGG Q
Explore Perilipin-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets